Table 2. Anti-CHIKV seropositivity rate in the study population (N = 1,544).
| Variable | Number | IgG positive (%) | IgM positive (%) | IgG and IgM positive (%) | IgG and/or IgM positive (%) |
|---|---|---|---|---|---|
| Age (years) | |||||
| ≤5 | 268 | 40 (14.9) | 27 (10.1) | 3 (7.5) | 64 (23.9) |
| 6–15 | 701 | 164 (23.4) | 61 (8.7) | 20 (12.2) | 205 (29.2) |
| 16–45 | 554 | 221 (39.9) | 46 (8.3) | 21 (9.5) | 246 (44.4) |
| ≥46 | 21 | 17 (80.9) | 3 (14.3) | 2 (11.8) | 18 (85.7) |
| Region | |||||
| Mandalay | 927 | 187 (20.2) | 75 (8.1) | 19 (10.2) | 243 (26.2) |
| Myeik | 104 | 33 (31.7) | 19 (18.3) | 8 (24.2 | 44 (42.3) |
| Yangon | 513 | 222 (43.6) | 43 (8.4) | 19 (8.6) | 246 (47.9) |
| Gender | |||||
| Female | 602 | 154 (25.6) | 51 (8.5) | 13 (8.4) | 192 (31.9) |
| Male | 942 | 288 (30.5) | 86 (9.2) | 33 (11.5) | 341 (36.2) |
| Health status | |||||
| Febrile patients | 610 | 152 (24.9) | 48 (7.9) | 15 (9.7) | 185 (30.3) |
| Healthy volunteers | 934 | 290 (31.1) | 89 (9.5) | 31 (10.7) | 348 (37.3) |
| Year | |||||
| 2013 | 280 | 83 (29.6) | 13 (4.6) | 6 (7.2) | 90 (32.1) |
| 2015 | 330 | 69 (20.9) | 35 (10.6) | 9 (13.0) | 95 (28.8) |
| 2018 | 934 | 290 (31.1) | 89 (9.5) | 31 (10.7) | 348 (37.3) |
| Overall | 1544 | 442 (28.6) | 137 (8.9) | 46 (3.0) | 533 (34.5) |